Physical Therapy for Parkinson's Disease

Cleveland Clinic, Cleveland, OH
Methylphenidate +2 morePhase < 1RecruitingLed by Shnehal PatelResearch Sponsored by Hubert Fernandez

Study Summary

This trial will compare physical therapy alone to physical therapy plus medication (either low dose methylphenidate or atomoxetine) to see if the addition of medication leads to more improvement in gait and balance in patients with Parkinson disease.

Eligible Conditions
  • Parkinson's Disease


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Balance Evaluation
Secondary outcome measures
Change in gait
Other outcome measures
Motor function

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

3Treatment groups
Active Control
Group I: Physical TherapyActive Control1 Intervention
Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
Group II: Physical Therapy plus MethylphenidateActive Control2 Interventions
Methylphenidate 20 mg daily in combination with PT
Group III: Physical Therapy plus AtomoxetineActive Control2 Interventions
Atomoxetine 10 mg daily in combination with PT or PT alone.

Find a site

Who is running the clinical trial?

Hubert FernandezLead Sponsor
Shnehal PatelPrincipal Investigator
The Cleveland Clinic

Media Library

Physical Therapy Clinical Trial Eligibility Overview. Trial Name: NCT02879136 — Phase < 1
Parkinson's Disease Research Study Groups: Physical Therapy, Physical Therapy plus Methylphenidate, Physical Therapy plus Atomoxetine
Parkinson's Disease Clinical Trial 2023: Physical Therapy Highlights & Side Effects. Trial Name: NCT02879136 — Phase < 1
Physical Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT02879136 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the aggregate populace of participants taking part in this research?

"Affirmative. The medical trial is actively looking for participants, as evidenced by the information on which was last updated February 15th 2022 - shortly after being posted December 1st 2016. 42 patients are sought from a single location to take part in this study."

Answered by AI

Who has the necessary qualifications for taking part in this research project?

"This medical trial is seeking 42 individuals suffering from Parkinson's Disease, aged 18-90. To be considered for enrolment, patients must have a score of 2 or higher in the UPDRS 3.10 item 'independent walking but with substantial gait impairment; not related to off periods'. Furthermore, their dopaminergic treatment must remain consistent during the next month."

Answered by AI

Are there enrollment opportunities for this clinical exploration at present?

"Per the details available on, this investigation is presently enrolling participants in its research cohort. The trial was initially published online on December 1st 2016 and recently updated February 15th 2022."

Answered by AI

What have prior research efforts divulged about the combination of Physical Therapy and Atomoxetine?

"At present, 4 Phase 3 trials investigating the combination of Physical Therapy and Atomoxetine are ongoing. There is a concentration of studies centered in Houston, Texas but altogether there are 126 locations running this clinical research."

Answered by AI

Are individuals over 85 years of age being accepted into this research program?

"This clinical trial has established that 18 is the minimum age of participation, while 90 years old represent the cut-off for qualifications."

Answered by AI
~6 spots leftby Dec 2024